BeOne Medicines Secures Up to $950 Million Through IMDELLTRA Royalty Deal
BeOne Medicines Strikes $950 Million Royalty Deal with Royalty Pharma for IMDELLTRA, Strengthening Oncology Strategy and Financial Flexibility BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused…
Devonian Issues Corporate Update and Details on Ongoing Private Placement
Devonian Health Group Provides Strategic Corporate Update and Clarifies Details of Private Placement Financing Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company…
AAHI Partners with Quratis to Boost Worldwide Vaccine Production and Availability
AAHI and Quratis Forge Strategic Partnership to Transform Global Vaccine Manufacturing and Expand Access to Lifesaving Immunizations In a landmark development for global health equity, the Access to Advanced Health…
Quanterix Accelerator Lab Secures Prestigious New York State Clinical Laboratory Permit
Quanterix Accelerator Laboratory Secures New York State Clinical Laboratory Permit, Expanding Biomarker Research and Clinical Testing Capabilities Nationwide Quanterix Corporation (NASDAQ: QTRX), a biotechnology company recognized for revolutionizing precision medicine…
SMSbiotech Launches First-in-Human Phase 1 Clinical Trial Targeting COPD
SMSbiotech Advances to First-in-Human Phase 1 Clinical Trial for COPD with Innovative Stem Cell Therapy San Diego-based regenerative medicine company begins groundbreaking trial in Australia, aiming to restore lung function…
Altasciences Selected by Steel Therapeutics to Lead Pivotal Toxicology Study for Fizurex™
Altasciences Chosen by Steel Therapeutics to Advance Pivotal Toxicology Study for Fizurex™ Altasciences, a leading provider of integrated drug development solutions, announced that it has been selected by Steel Therapeutics,…
Strand Therapeutics Names Dr. Jason J. Luke as New Chief Medical Officer
Strand Therapeutics Strengthens Leadership with Appointment of Dr. Jason J. Luke as Chief Medical Officer Strand Therapeutics, a biotechnology company pioneering programmable messenger RNA (mRNA) medicines, has announced the appointment…
PureTech Highlights IPF Phase 2b Data and Patient Insights
PureTech Showcases Differentiated IPF Strategy, Highlights Patient Insights, and Positions Deupirfenidone as a Potential New Standard of Care PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company devoted…
NEJM to Publish Savara’s Phase 3 IMPALA-2 Trial Results in Autoimmune PAP
Savara’s Landmark IMPALA-2 Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis to Be Published in The New England Journal of Medicine Savara Inc. (Nasdaq: SVRA), a clinical-stage…
Sarepta Therapeutics to Refinance $700 Million of 1.25% Convertible Senior Notes Due 2027
Sarepta Therapeutics Restructures $700 Million in Convertible Debt, Extending Maturities and Strengthening Financial Flexibility Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine focused on rare diseases, has…
Develop Health Secures $14.3M to Streamline Prior Authorization and Drug Access with GenAI
Develop Health Raises $14.3 Million Series A to Automate Prior Authorization and Medication Access with Generative AI Develop Health, a fast-growing healthcare technology company focused on modernizing benefits verification and…
Circle Pharma Publishes Nature Study on Novel Cancer Therapy
Circle Pharma’s Nature Publication Highlights Breakthrough in Cyclin A/B RxL Inhibition and Preclinical Anti-Tumor Activity Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers,…